Candel Therapeutics, Inc.
CADLDrugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
15dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How CADL's past catalysts played out
aglatimagene besadenovec
Prostate Cancer
Aglatimagene besadenovec + valacyclovir
Prostate Cancer
Valacyclovir
Non-squamous, Non-Small Cell Lung Cancer
CAN-2409
Malignant Glioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
aglatimagene besadenovec | Phase 3 | Prostate Cancer | - | - |
Aglatimagene besadenovec + valacyclovir | Phase 3 | Prostate Cancer | - | - |
Valacyclovir | Phase 3 | Non-squamous, Non-Small Cell Lung Cancer | - | - |
CAN-2409 | Phase 2 | Malignant Glioma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Candel Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Candel Therapeutics, Inc.'s (CADL) pipeline across Phase 3, Phase 2. Its lead program is aglatimagene besadenovec (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Candel Therapeutics, Inc.'s next FDA catalyst?→
Candel Therapeutics, Inc.'s (CADL) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CADL biotech catalysts?→
Add CADL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Candel Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.